News - Page 159 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to Evaluate DMT in a Comparative Clinical Study

PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to Evaluate DMT in a Comparative Clinical Study

Post published:August 25, 2021
Post category:Press Release

Read more about the article Clinical Director of Imperial College’s Center for Psychedelic Research Joins Entheon Advisory Board

Clinical Director of Imperial College’s Center for Psychedelic Research Joins Entheon Advisory Board

Post published:August 25, 2021
Post category:Press Release

Read more about the article Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida

Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida

Post published:August 24, 2021
Post category:Press Release

Read more about the article Mindset Pharma Broadens its IP Portfolio by Filing U.S. Provisional Patent Extending its DMT and 5-MeO-DMT Inspired Psychedelic Drug Candidates

Mindset Pharma Broadens its IP Portfolio by Filing U.S. Provisional Patent Extending its DMT and 5-MeO-DMT Inspired Psychedelic Drug Candidates

Post published:August 24, 2021
Post category:Press Release

Read more about the article CB Therapeutics Expands Biomanufacturing IP Portfolio

CB Therapeutics Expands Biomanufacturing IP Portfolio

Post published:August 24, 2021
Post category:Press Release

Read more about the article MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders

MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders

Post published:August 24, 2021
Post category:Press Release

Read more about the article Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan

Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan

Post published:August 24, 2021
Post category:Press Release

Read more about the article Psychedelic Bulletin: Beckley Psytech Raises $80m in Series B; Bright Minds Biosciences Reports Positive Preclinical Findings; Psychedelics DNA Test Called Into Question

Psychedelic Bulletin: Beckley Psytech Raises $80m in Series B; Bright Minds Biosciences Reports Positive Preclinical Findings; Psychedelics DNA Test Called Into Question

Post published:August 20, 2021
Post category:Psychedelic Bulletin

Read more about the article Cybin Files Two Additional International Patent Applications in Support of the Company’s Research Phase Programs

Cybin Files Two Additional International Patent Applications in Support of the Company’s Research Phase Programs

Post published:August 19, 2021
Post category:Press Release

Read more about the article Wesana Health Highlights Recent Appointments to Board of Directors

Wesana Health Highlights Recent Appointments to Board of Directors

Post published:August 19, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.